drugset
drugset / Trial / NCT04933682

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

NCT04933682 ↗

Phase 1 Completed 16 enrolled Alexion Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a 2-part, open label, fixed-sequence study to evaluate the potential drug interaction between ALXN2050 and fluconazole (Part 1), and between ALXN2050 and rifampin (Part 2) in healthy adult participants. Part 1 will be a 2-period, fixed-sequence study. Part 2 will be a single-period, fixed-sequence study.

Timeline

Start
2021-06-07
Primary completion
2021-08-23
Completion
2021-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluconazole Small molecule — Oral
Subject Rifampin Small molecule — Oral
Subject Vemircopan Small molecule — Oral

Indications

No indication recorded.